Furthermore, the establishment of aggressive breast cancer phenotype following upregulation of NEDD9 is accompanied by increased expression of serglycin, its cell surface binding partner CD44, and CS synthesizing enzymes [24]. This evidence concerns the gene SRGN and breast cancer.